[go: up one dir, main page]

IL129327A0 - Method of preventing allograft rejection - Google Patents

Method of preventing allograft rejection

Info

Publication number
IL129327A0
IL129327A0 IL12932799A IL12932799A IL129327A0 IL 129327 A0 IL129327 A0 IL 129327A0 IL 12932799 A IL12932799 A IL 12932799A IL 12932799 A IL12932799 A IL 12932799A IL 129327 A0 IL129327 A0 IL 129327A0
Authority
IL
Israel
Prior art keywords
allograft rejection
preventing allograft
preventing
rejection
allograft
Prior art date
Application number
IL12932799A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL129327A0 publication Critical patent/IL129327A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
IL12932799A 1998-04-16 1999-04-05 Method of preventing allograft rejection IL129327A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8198398P 1998-04-16 1998-04-16

Publications (1)

Publication Number Publication Date
IL129327A0 true IL129327A0 (en) 2000-02-17

Family

ID=22167652

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12932799A IL129327A0 (en) 1998-04-16 1999-04-05 Method of preventing allograft rejection

Country Status (8)

Country Link
EP (1) EP0963755A3 (fr)
JP (1) JPH11335283A (fr)
KR (1) KR19990083196A (fr)
AU (1) AU2379499A (fr)
CA (1) CA2269046A1 (fr)
HU (1) HUP9901211A3 (fr)
IL (1) IL129327A0 (fr)
ZA (1) ZA992739B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
JP2018531213A (ja) 2015-03-13 2018-10-25 フォーマ セラピューティクス，インコーポレイテッド Ｈｄａｃ８阻害剤としてのアルファ−シンナミド化合物及び組成物
US10029995B2 (en) 2015-09-03 2018-07-24 Forma Therapeutics, Inc. [6,6] fused bicyclic HDAC8 inhibitors
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015066A1 (fr) * 1992-01-23 1993-08-05 Pfizer Inc. Benzopyranne et antagonistes du ltb4 apparentes
MX9300312A (es) * 1992-01-23 1993-07-31 Pfizer Antagonistas benzopiranicos y relacionado de ltb.
CN1166834A (zh) * 1994-10-13 1997-12-03 美国辉瑞有限公司 苯并吡喃和苯并稠合化合物，其制备方法和它们作为白三烯b4(ltb4)拮抗剂的用途
CA2201742A1 (fr) * 1994-10-13 1996-04-25 Anthony Daniel Piscopio Composes de benzopyranne et composes benzo-fusionnes, leur preparation et leur utilisation comme antagonistes de leucotriene b4 (ltb4)
IL121931A (en) * 1996-10-17 2000-02-17 Pfizer Pharmaceutical compositions for preventing allograft rejection
IL128731A0 (en) * 1998-03-12 2000-01-31 Pfizer Prod Inc Method of preventing allograft rejection

Also Published As

Publication number Publication date
KR19990083196A (ko) 1999-11-25
JPH11335283A (ja) 1999-12-07
ZA992739B (en) 2000-10-16
EP0963755A2 (fr) 1999-12-15
HU9901211D0 (en) 1999-06-28
AU2379499A (en) 1999-10-28
HUP9901211A3 (en) 2001-09-28
HUP9901211A2 (hu) 2001-06-28
EP0963755A3 (fr) 2001-03-14
CA2269046A1 (fr) 1999-10-16

Similar Documents

Publication Publication Date Title
IL121186A0 (en) Stent fabrication method
GB9828640D0 (en) Novel method and compounds
AU6073499A (en) Method to prevent xenograft transplant rejection
GB9824335D0 (en) Mirror and method of making the same
IL124293A0 (en) Method and compositions for the reduction of xenotransplantation rejection
PL335075A1 (en) Method of obtaining eprosartane
HU9901211D0 (en) Method of preventing allograft rejection
IL128731A0 (en) Method of preventing allograft rejection
GB9713538D0 (en) Fabrication method of cmos device
IL152739A0 (en) Method for preventing allograft rejection
PL334901A1 (en) Method of obtaining benzothiazolones
IL137439A0 (en) Method for the determination of prosthetic infections
IL143048A0 (en) Expandable stent and method for manufacturing same
PL339188A1 (en) Method of obtaining oxaphosphorin-2-amines
GB2357917B (en) Method of fabrication of step edge
IL121931A0 (en) Method of preventing allograft rejection
EP0874707A4 (fr) Procede de fabrication d'un composant rainure
HUP0103174A3 (en) Method of communication
PL336266A1 (en) Method of obtaining epsilon-caprolactams
AU1752999A (en) Method for preventing transplant rejection
EP1143993A4 (fr) Procede de suppression du rejet aigu persistant d'une greffe allogenique
GB2341271B (en) Method of fabricating capacitor
GB2336714B (en) Method of fabricating capacitor
GB9812706D0 (en) Jewellery securing method
IL152109A0 (en) Stent fabrication method